Wedbush Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Positive 64.2%

Neg 0% Neu 0% Pos 64.2%

Wedbush analyst David Nierengarten initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Outperform rating and announces Price Target of $35.